3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
1
Dementia
1
Alzheimer Disease
1
Interventions
Cisplatin
22
Magnetic Resonance Spectroscopy
18
Gemcitabine
15
Carboplatin
14
pembrolizumab
13
Specimen Handling
13
Paclitaxel
13
Radiotherapy
10
Nivolumab
10
Bevacizumab
10
atezolizumab
8
Radiation
8
Platinum
8
Pemetrexed
8
Doxorubicin
8
Docetaxel
8
1,2-diaminocyclohexaneplatinum II citrate
8
Drug Therapy
7
Dexamethasone
7
Temozolomide
6
Rituximab
6
Radiotherapy, Intensity-Modulated
6
Prednisone
6
Surgical Procedures, Operative
5
Ipilimumab
5
Immunoglobulin G
5
Disulfides
5
Cytarabine
5
Cyclophosphamide
5
Biopsy
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
UE2343
×
90 days
×
Clear all
NCT06125951
2026-04-23
XanaMIA
Actinogen Medical
Phase 2/3
Active not recruiting
247 enrolled